Senti Biosciences Operating Income Over Time
| SNTI Stock | USD 0.98 0.03 3.27% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Senti Biosciences Performance and Senti Biosciences Correlation. Is there potential for Biotechnology market expansion? Will Senti introduce new products? Factors like these will boost the valuation of Senti Biosciences. If investors know Senti will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Senti Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.95) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Senti Biosciences is measured differently than its book value, which is the value of Senti that is recorded on the company's balance sheet. Investors also form their own opinion of Senti Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Senti Biosciences' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Senti Biosciences' market value can be influenced by many factors that don't directly affect Senti Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Senti Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Senti Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Senti Biosciences' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Senti Biosciences and related stocks such as Karyopharm Therapeutics, X4 Pharmaceuticals, and Century Therapeutics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KPTI | (10.3 M) | (10.3 M) | (15.9 M) | (34 M) | (75.8 M) | (119.1 M) | (110.7 M) | (130.5 M) | (179.9 M) | (189.3 M) | (171.8 M) | (98.3 M) | (142.2 M) | (129.5 M) | (119.4 M) | (90.7 M) | (95.2 M) |
| XFOR | (14.8 M) | (14.8 M) | (14.8 M) | (14.8 M) | (14.8 M) | (14.8 M) | (24.3 M) | (36.1 M) | (45.9 M) | (51.7 M) | (59.9 M) | (85.1 M) | (87.6 M) | (107.5 M) | (36.4 M) | (32.8 M) | (34.4 M) |
| IPSC | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (20 M) | (49.2 M) | (94.9 M) | (133.8 M) | (146.5 M) | (138.1 M) | (124.3 M) | (130.5 M) |
| BRNS | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (25.7 M) | (20 M) | (45.2 M) | (4 M) | (83.9 M) | (68 M) | (61.2 M) | (64.2 M) |
| COEP | (10.1 K) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (14 M) | (34.2 M) | (21.5 M) | (10.1 M) | (9 M) | (9.5 M) |
| CVM | (2.8 M) | (17.2 M) | (19.9 M) | (27.6 M) | (34.3 M) | (25.6 M) | (21.3 M) | (16.8 M) | (20.2 M) | (29 M) | (36.2 M) | (36.1 M) | (31.5 M) | (26.4 M) | (24.8 M) | (22.3 M) | (21.2 M) |
| CUE | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (7.7 M) | (23.2 M) | (38.7 M) | (36.8 M) | (45 M) | (43.7 M) | (53.2 M) | (52.1 M) | (41.5 M) | (37.4 M) | (39.2 M) |
| ALGS | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (13.7 M) | (54 M) | (97.8 M) | (128.3 M) | (97.6 M) | (88.1 M) | (89.2 M) | (80.2 M) | (84.3 M) |
| GNTA | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (4.6 M) | (5.6 M) | (5.7 M) | (11 M) | (11.7 M) | (9.8 M) | (8.8 M) | (9.2 M) |
Senti Biosciences and related stocks such as Karyopharm Therapeutics, X4 Pharmaceuticals, and Century Therapeutics Operating Income description
Operating Income is the amount of profit realized from Senti Biosciences operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Senti Biosciences is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Senti Biosciences | SNTI |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2 Corporate Drive, |
| Exchange | NASDAQ Exchange |
USD 0.9811
Check out Senti Biosciences Performance and Senti Biosciences Correlation. For more detail on how to invest in Senti Stock please use our How to Invest in Senti Biosciences guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Senti Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.